Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Maxim starts Amryt Pharma at buy; PT $27

Maxim Group launched coverage of Amryt Pharma plc (NASDAQ, AIM:AMYT) with a “buy” rating and $27 price target. The stock closed at $13.84 on March 30. Amryt is a commercial rare disease company globally marketing...

March 31, 2021

Markets

Echelon starts CareRx at buy; PT $7.25 (Canadian)

Echelon Capital Markets initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and price target of $7.25 (Canadian). The stock closed at $5.39 on March 29. CareRx is Canada’s leading pharmacy services provider for...

March 30, 2021

Markets

Cantor starts PAVmed at OW; PT $8

Cantor Fitzgerald initiated coverage of PAVmed (NASDAQ:PAVM) with an “overweight” rating and price target of $8. The stock closed at $3.93 on March 29. The company employs a unique business model that emphasizes capital...

March 29, 2021

Markets

Cantor starts Aytu BioPharma at OW; PT $11

Cantor Fitzgerald launched coverage of Aytu BioPharma (NASDAQ:AYTU) with an “overweight” rating and $11 price target. The stock closed at $7.49 on March 29. “Through a strategy of in-licensing and acquisition-based...

March 29, 2021

Markets

Leede Jones Gable starts Perimeter Medical Imaging at speculative buy; PT $6.75 (Canadian)

Leede Jones Gable initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and price target of $6.75 (Canadian). The stock closed at $4.30 on March 26. The firm’s lead medical device...

March 29, 2021

Markets

Maxim cuts Co-Diagnostics to hold; removes PT

Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its priced target, citing COVID-19 testing and revenue growth, which appear “to have peaked.” The stock closed at $9.70 on March 26...

March 29, 2021

Markets

Leede Jones Gable starts Cardiol Therapeutics at speculative buy; PT $12.50 (Canadian)

Leede Jones Gable initiated coverage of Cardiol Therapeutics (TSX:CRDL) with a “speculative buy” rating and price target of $12.50 (Canadian). The stock closed at $4.51 on March 24. Analyst Doug Loe, Ph.D., writes that...

March 25, 2021

Markets

BTIG starts iCAD at buy; PT $25

BTIG initiated coverage of iCAD (NASDAQ:ICAD) with a “buy” rating and a price target of $25. The stock closed at $19.35 on March 22. iCAD is a medical technology company focused on cancer care, offering both cutting...

March 23, 2021

Markets

Cantor starts Eledon Pharma at OW; PT $25

Cantor Fitzgerald launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “overweight” rating and $25 price target. The stock closed at $13.65 on March 22. Eledon is focused on developing AT-1501, which is an...

March 22, 2021

Markets

HCW starts MiMedx at buy; PT $20

H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...

March 19, 2021

Markets

WB cuts Acutus Medical to market perform

William Blair downgraded Acutus Medical (NASDAQ:AFIB) to “market perform,” saying “early-stage growing pains lead to lower than expected guidance.” The stock closed at $16.83, down $2.23, on March 18. Analyst Margaret...

March 19, 2021

Markets

SVB Leerink starts Merus at OP; PT $33

SVB Leerink launched coverage of Merus NV (NASDAQ:MRUS) with an “outperform” rating and $33 price target. The stock closed at $22.04 on March 15. Merus is focused on developing novel bispecific and trispecific...

March 16, 2021

Markets

Maxim starts Oncorus at buy; PT $35

Maxim Group initiated coverage of Oncorus (NASDAQ:ONCR) with a “buy” rating and price target of $35. The stock closed at $16.39 on March 15. Oncorus is developing oncolytic viral (OV) immunotherapies for solid tumors...

March 16, 2021

Markets

SVB Leerink ups Solid Biosciences to OP from MP; PT to $15 from $3

SVB Leerink upgraded Solid Biosciences (NASDAQ:SLDB) to “outperform” from “market perform” and raised its price target to $15 from $3, citing the first functional data for the company’s microdystrophin gene...

March 16, 2021

Markets

Canaccord ups TransMedics PT to $79 from $46

Canaccord Genuity raised its price target for TransMedics Group (NASDAQ:TMDX) to $79 from $46, saying the company has the “technology that will become the standard of care for organ transplant and in the process...

March 15, 2021

Markets

BTIG starts Seelos Therapeutics at buy; PT $14

BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...

March 12, 2021

Markets

WB ups Selecta Biosciences to outperform

William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11. The company’s ImmTOR platform...

March 12, 2021

Markets

SVB Leerink starts Aldeyra Therapeutics at OP; PT $22

SVB Leerink launched coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with an “outperform” rating and $22 price target. The stock closed at $12.07 on March 11. Two of the company’s lead investigational compounds...

March 12, 2021

Markets

Maxim doubles Entera Bio PT to $10 from $5 on new data; shares soar

Maxim Group raised its price target for Entera Bio (NASDAQ:ENTX) to $10 from $5, citing updated data from an ongoing Phase 2 trial of oral parathyroid hormone candidate, EB613, in osteoporosis. At midday on March 11...

March 11, 2021

Markets

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

March 10, 2021

Markets

Cantor starts Auxly Cannabis at OW; PT $85 cents (Canadian)

Cantor Fitzgerald initiated coverage of Auxly Cannabis Group (TSXV:XLY) with an “overweight” rating and price target of 85 cents (Canadian). The stock closed at 36 cents on March 9. Auxly is the number one player in...

March 10, 2021

Markets

Maxim starts Panbela Therapeutics at buy; PT $8

Maxim Group launched coverage of Panbela Therapeutics (NASDAQ:PBLA) with a “buy” rating and $8 price target. The stock closed at $4.17 on March 9. The company’s polyamine metabolic inhibitor drug candidate, SBP...

March 10, 2021

Subscribe